Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
Article
Stiefel Laboratories to acquire Barrier Therapeutics
Coral Gables, Fla. - Stiefel Laboratories has announced it has signed a definitive merger agreement to acquire Barrier Therapeutics, according to PRNewswire.
Coral Gables, Fla.
- Stiefel Laboratories has announced it has signed a definitive merger agreement to acquire Barrier Therapeutics, according to PRNewswire.
The transaction is valued at approximately $148 million, and is subject to valid tender of a majority of Barrier Therapeutics' fully diluted common stock, regulatory approvals and other customary conditions.
Related Videos
Related Content
